ANP
vs
S
S&P/ASX 300
ANP
Over the past 12 months, ANP has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +5% growth.
Stocks Performance
ANP vs S&P/ASX 300
Performance Gap
ANP vs S&P/ASX 300
Performance By Year
ANP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Antisense Therapeutics Ltd
Glance View
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.